Category: News

(La Voz de Galicia) La Fundación Pública Galega de Medicina Xenómica (FPGMX) diagnostica 20.000 pacientes al año. La mitad, de tumores, de los que 8.000 se tratan en servicios de Oncohematología y 2.000 son hereditarios, sobre todo de mama, ovario, colon y recto. Los otros 10.000 casos son enfermedades genéticas raras, de todos los servicios hospitalarios. «Somos el centro de Genómica de mayor volumen de España. Podemos diagnosticar cualquier enfermedad genética rara, aunque no siempre es posible encontrar la causa», afirma Ángel Carracedo, quien, con Fernando Domínguez, dirige este centro del Servizo Galego de Saúde (Sergas).

View more 

La Fundación Ramón Areces acaba de adjudicar 475.745 euros a cuatro nuevos proyectos de investigación gallegos sobre cáncer, enfermedades raras, seguridad alimentaria y energía renovable. Los cuatro proyectos fueron seleccionados de entre 631 investigaciones presentadas al concurso nacional de Ayudas a la Investigación en Ciencias de la Vida y de la Materia que la institución convoca bianualmente.
Con este concurso, la Fundación Ramón Areces pretende contribuir a consolidar una sólida estructura científica y tecnológica en nuestro país, prestando apoyo a los jóvenes. La fundación cede a los autores los derechos de propiedad intelectual o industrial que puedan derivarse de la ejecución de cada proyecto.
En los seleccionados en esta ocasión trabajarán 21 científicos gallegos durante los próximos tres años, y serán dirigidos por el catedrático de la USC Ángel Carracedo Álvarez, director de la Fundación Pública Galega de Medicina Xenómica; Miguel Ángel Fidalgo Pérez, del Centro de Investigación en Medicina Molecular (USC); Jorge Pérez Juste de la Facultad de Química (UVigo), y por Carlos Vázquez Vázquez de la Facultad de Química (USC).

 

Read more 

Video 1: Welcome – click here

Video 2: Vincenzo L. Pascali “Ethical and legal aspects of giant database storage”– click here

Video 3. Ana Marzo “Legal horizons in the treatment of genomic data” – click here

Video 4. Ferrán Sanz “Data protection in the cloud” – click here

Video 5. Carlos Romeo “Health Big Data and the Cloud: a new challenge for law” – click here

Video 6. Discussion – click here

Continue Reading

simposio

Next Wednesday, December 14th, will take place in Barcelona the mini-symposium “Private health data in the cloud”.

This event, organized by the PanCanRisk consortium (pancanrisk.eu) is aimed mainly at research groups and organizations, Students, Project Managers Patients and Legal Advisers interested in the protection of health data, especially genetic data.

The objective is to analyze the novelties of the new European Law of data protection and to comment with experts in the matter ethical and legal issues and the need to conciliate data security with the anonymity that is needed to preserve the identity of subjects that are tested at the clinical trials and research projects.

While data is being produced, analyzed and reanalysed at a very high speed, we lack a common ethical and legal framework to facilitate genomic and clinical data, global science collaboration, and responsible research conduct. An international code of conduct should be designed to enable global genomic and clinical data sharing for biomedical research within a human rights framework has been proposed.

In the following link you can find the program.

Registration is free, but please confirm your assistance by mail (info@pancanrisk.eu) in order to access to the PRBB building.

We look forward to your participation and welcome your feedback via Twitter at @pancanrisk and with the HT #PrivateHealthData

 

fotocarracedo

‘Nature’ published the study led by Fundación Galega de Medicina Xenómica and USC 

Researchers at the National Center for Cardiovascular Research Carlos III (CNIC) in collaboration with the University of Santiago de Compostela and Zaragoza, the Medical Research Council UK and the Fundación Pública Galega de Medicina Xenómica (Sergas) demonstrated how the combination and interaction our two genomes, nuclear and mitochondrial, triggers a cellular adaptation that will have repercussions throughout our lives and that will determine the quality of aging.

Click here for more information

Researchers have studied data from the International Cancer Genome Consortium (ICGC) and found that insertions of genes or parts of genes are commonplace in cancer genomes

Rearrangement of the genome is common in cancer – for example, deletions, rearrangements and inversions. However, little is known about insertions into the genome and the role they play in cancer.

To address this, the EU-funded CANCER INSERTOME (The landscape and functional impact of tumour-specific genomic insertions of 1,000 cancer genomes) initiative studied massive quantities of cancer genome data.

Insertions in the DNA arise from either transposable elements, DNA that can move around the genome, or viruses that insert themselves at random. This process is known as retrotransposition, and this is what researchers searched for.

CANCER INSERTOME found that retrotransposition occurs at least once in about half of all cancers, and more commonly in lung and colorectal cancers. For these cancers, the rates are 93 % and 75 %, respectively.

Researchers also identified a mutation process in cancer cells called L1-mediated 3′ transduction, which made up about a quarter of all retrotranspositions studied. Of these, over 2 % involved relocation of entire genes or gene regions.

This project has helped to highlight the importance of retrotransposition in cancer genomics. The understanding generated by this project will help cancer biologists fight the disease in the long term.